Balyasny Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Balyasny Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-871,409	Closed	-$5.24M	–	3447
2022 Q4	$5.24M	Buy	+871,409	New	+$4.76M	0.01%	1001
2022 Q3	–	Sell	-102,333	Closed	-$611K	–	3485
2022 Q2	$611K	Buy	102,333 +58,197	+132%	+$298K	﹤0.01%	1917
2022 Q1	$206K	Buy	+44,136	New	+$132K	﹤0.01%	2012
2019 Q2	–	Sell	-218,273	Closed	-$212K	–	1862
2019 Q1	$212K	Sell	218,273 -704,382	-76%	-$742K	﹤0.01%	1347
2018 Q4	$677K	Buy	922,655 +622,655	+208%	+$1.02M	﹤0.01%	1017
2018 Q3	$648K	Sell	300,000 -12,916	-4%	-$32K	﹤0.01%	1303
2018 Q2	$1.56M	Buy	+312,916	New	+$1.37M	0.01%	1012

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Balyasny Asset Management's CTIC Position: Q1 2023 in Review

Balyasny Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 871,409 shares — an estimated $5.24M sold.

Balyasny Asset Management first reported a position in CTIC in Q2 2018 and held it in 7 quarters. The position peaked at $5.24M in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

Balyasny Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
Balyasny Asset Management sold 871,409 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $5.24M.
Balyasny Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2018 and held it in 7 quarters.
Balyasny Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $5.24M in Q4 2022.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.